WeHealth Digital Medicine, Servier Group’s eHealth division, and Lucine, a pioneering French innovative company specialising in digital therapeutics (also known as DTx1), have announced their joint development partnership and distribution license. This is the first eHealth partnership between two French companies in the field of digital therapeutics.
The 10-year agreement was signed a few days after the first DTx Europe-DTx France event held in Bordeaux, and combines the expertise of WeHealth Digital Medicine and Lucine to offer patients and health care professionals digital therapies that fall within Servier Group’s therapeutic areas.
‘Through our partnership with Lucine, WeHealth Digital Medicine has joined the world of DTx – solutions designed to treat patients directly by administering proven digital therapies, thus bringing new hope to millions of patients,’ says Dr David Guez, director of WeHealth Digital Medicine.
According to the terms of the agreement, WeHealth Digital Medicine will help to cover development costs, including clinical trials, and will pay royalties to Lucine on future sales.
Digital therapeutics, also called DTx, are solutions that offer a therapeutic effect proven through robust clinical trials. They can be used alone or combined with medication in order to improve patients’ health.
‘This partnership with WeHealth Digital Medicine, whose human and environmental values are similar to our own, will make it possible to accelerate tomorrow’s medicine. DTx are the most promising innovations in delivering personalized care to patients, especially those with chronic disease. We are talking about action that is both physiological and biological and opens up new possibilities in the range of treatments available to health care professionals,’ says Maryne Cotty-Eslous, CEO of Lucine.
Commercialisation of the first solutions is scheduled for 2021.
1 Therapeutic solution delivered by software to treat/prevent/relieve symptoms and/or disease.